Cargando…
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovag...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445446/ https://www.ncbi.nlm.nih.gov/pubmed/36059275 http://dx.doi.org/10.1177/23247096221123144 |